Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
NEW YORK - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a pharmaceutical company with a market capitalization of $2.46 billion and annual revenue of $9.7 billion, has appointed Michael Goettler and Sandra Leung to its Board of Directors, effective July 22, 2025, expanding the board from ten to twelve members.
Goettler, former Chief Executive Officer of Viatris, will serve on the Talent and Compensation Committee and Science and Technology Committee. Leung, who previously held the position of Executive Vice President and General Counsel at Bristol Myers Squibb Company, will join the Nominating and Corporate Governance Committee.
"On behalf of our Board, I am delighted to welcome Michael and Sandra to the Bausch Health Board," said John A. Paulson, Chairperson of the Bausch Health Board, in a press release statement. "Their deep industry knowledge and leadership experience will provide invaluable guidance as the organization continues to evolve and strengthen."
Goettler brings leadership experience from his time at Viatris, where he led the company through transformation efforts. Leung contributes expertise in corporate governance, compliance, and regulatory initiatives from her career at Bristol Myers Squibb.
Bausch Health Companies is a global pharmaceutical company with operations across gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, including through its controlling interest in Bausch + Lomb Corporation. For detailed analysis and additional insights about Bausch Health’s performance and outlook, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Bausch Health Companies reported mixed first-quarter results. The company saw strong revenue and adjusted EBITDA in most segments, with notable performances from Salix and Solta. Salix exceeded expectations by 3%, driven by an 8% year-over-year increase in its key product, Xifaxan. Solta achieved a 13% positive surprise against projections, with a 28% year-over-year growth fueled by market expansions in South Korea and China. Meanwhile, Raymond James adjusted its outlook on Bausch Health, lowering the price target from $9.00 to $8.00 but maintaining a Market Perform rating, citing challenges in the Bausch + Lomb/International segment.
In product news, Health Canada has approved Bausch Health’s Thermage FLX, a non-invasive skin tightening and contouring device. This new system offers faster treatments and improved patient comfort with its advanced technology. Additionally, Bausch Health launched Fraxel FTX™, a new skin resurfacing laser, at the ASLMS 2025 Annual Conference. The Fraxel FTX™ system, designed for various skin concerns, will soon be available to professionals in the United States, with plans for global expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.